Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care

Amina Chaudhry, Michael Botsko, Linda Weiss, James E. Egan, Jennifer Mitty, Barbara Estrada, Gregory M Lucas, Tanita Woodson- Adu, Timothy P. Flanigan, David A. Fiellin

Research output: Contribution to journalArticle

Abstract

Objective: This study was part of a national, multisite demonstration project evaluating the impact of integrated buprenorphine/naloxone treatment and HIV care. The goals of this study were to describe the baseline demographic, clinical, and substance use characteristics of the participants and to explore HIV transmission risk behaviors in this group. Methods: Nine sites across the United States participated. Data obtained by interview and chart review included demographic information, medical history, substance use, and risk behaviors. We performed a descriptive analysis of patient characteristics at entry and used logistic regression to evaluate factors associated with 1) unprotected anal or vaginal sex; and 2) needle-sharing within the previous 90 days. Results: Three hundred eighty-six individuals were included in the study: 303 (78.5%) received buprenorphine/naloxone; 41 (10.6%) received methadone; and 42 (10.9%) received another form of treatment. The analysis of risk behaviors was limited to those in the buprenorphine group (n = 303). Among those reporting vaginal or anal sex in the previous 90 days, 24% had sex without a condom. Factors significantly associated with unprotected sex were: having a partner; female gender; and alcohol use in previous 30 days. A total of 8.9% of participants shared needles in the previous 90 days. Factors significantly associated with needle-sharing were: amphetamine use; marijuana use; homelessness; and anxiety. Conclusions: Addressing transmission risk behaviors is an important secondary HIV prevention strategy. In addition to treatment for opioid dependence, addressing other substance use, social issues, particularly housing, and mental health may have important implications for reducing HIV transmission in HIV-infected opioid-dependent patients.

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
Volume56
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 1 2011

Fingerprint

Risk-Taking
HIV
Needle Sharing
Opioid Analgesics
Demography
Unsafe Sex
Homeless Persons
Buprenorphine
Methadone
Condoms
Amphetamine
Cannabis
Secondary Prevention
Sexual Behavior
Needles
Mental Health
Therapeutics
Anxiety
Logistic Models
Alcohols

Keywords

  • buprenorphine
  • heroin dependence
  • HIV
  • methadone
  • opioid-related disorders

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. / Chaudhry, Amina; Botsko, Michael; Weiss, Linda; Egan, James E.; Mitty, Jennifer; Estrada, Barbara; Lucas, Gregory M; Woodson- Adu, Tanita; Flanigan, Timothy P.; Fiellin, David A.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 56, No. SUPPL. 1, 01.03.2011.

Research output: Contribution to journalArticle

Chaudhry, Amina ; Botsko, Michael ; Weiss, Linda ; Egan, James E. ; Mitty, Jennifer ; Estrada, Barbara ; Lucas, Gregory M ; Woodson- Adu, Tanita ; Flanigan, Timothy P. ; Fiellin, David A. / Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. In: Journal of Acquired Immune Deficiency Syndromes. 2011 ; Vol. 56, No. SUPPL. 1.
@article{8225e37c6bdd436b9d27f889c57022e3,
title = "Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care",
abstract = "Objective: This study was part of a national, multisite demonstration project evaluating the impact of integrated buprenorphine/naloxone treatment and HIV care. The goals of this study were to describe the baseline demographic, clinical, and substance use characteristics of the participants and to explore HIV transmission risk behaviors in this group. Methods: Nine sites across the United States participated. Data obtained by interview and chart review included demographic information, medical history, substance use, and risk behaviors. We performed a descriptive analysis of patient characteristics at entry and used logistic regression to evaluate factors associated with 1) unprotected anal or vaginal sex; and 2) needle-sharing within the previous 90 days. Results: Three hundred eighty-six individuals were included in the study: 303 (78.5{\%}) received buprenorphine/naloxone; 41 (10.6{\%}) received methadone; and 42 (10.9{\%}) received another form of treatment. The analysis of risk behaviors was limited to those in the buprenorphine group (n = 303). Among those reporting vaginal or anal sex in the previous 90 days, 24{\%} had sex without a condom. Factors significantly associated with unprotected sex were: having a partner; female gender; and alcohol use in previous 30 days. A total of 8.9{\%} of participants shared needles in the previous 90 days. Factors significantly associated with needle-sharing were: amphetamine use; marijuana use; homelessness; and anxiety. Conclusions: Addressing transmission risk behaviors is an important secondary HIV prevention strategy. In addition to treatment for opioid dependence, addressing other substance use, social issues, particularly housing, and mental health may have important implications for reducing HIV transmission in HIV-infected opioid-dependent patients.",
keywords = "buprenorphine, heroin dependence, HIV, methadone, opioid-related disorders",
author = "Amina Chaudhry and Michael Botsko and Linda Weiss and Egan, {James E.} and Jennifer Mitty and Barbara Estrada and Lucas, {Gregory M} and {Woodson- Adu}, Tanita and Flanigan, {Timothy P.} and Fiellin, {David A.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1097/QAI.0b013e318209d3b9",
language = "English (US)",
volume = "56",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care

AU - Chaudhry, Amina

AU - Botsko, Michael

AU - Weiss, Linda

AU - Egan, James E.

AU - Mitty, Jennifer

AU - Estrada, Barbara

AU - Lucas, Gregory M

AU - Woodson- Adu, Tanita

AU - Flanigan, Timothy P.

AU - Fiellin, David A.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Objective: This study was part of a national, multisite demonstration project evaluating the impact of integrated buprenorphine/naloxone treatment and HIV care. The goals of this study were to describe the baseline demographic, clinical, and substance use characteristics of the participants and to explore HIV transmission risk behaviors in this group. Methods: Nine sites across the United States participated. Data obtained by interview and chart review included demographic information, medical history, substance use, and risk behaviors. We performed a descriptive analysis of patient characteristics at entry and used logistic regression to evaluate factors associated with 1) unprotected anal or vaginal sex; and 2) needle-sharing within the previous 90 days. Results: Three hundred eighty-six individuals were included in the study: 303 (78.5%) received buprenorphine/naloxone; 41 (10.6%) received methadone; and 42 (10.9%) received another form of treatment. The analysis of risk behaviors was limited to those in the buprenorphine group (n = 303). Among those reporting vaginal or anal sex in the previous 90 days, 24% had sex without a condom. Factors significantly associated with unprotected sex were: having a partner; female gender; and alcohol use in previous 30 days. A total of 8.9% of participants shared needles in the previous 90 days. Factors significantly associated with needle-sharing were: amphetamine use; marijuana use; homelessness; and anxiety. Conclusions: Addressing transmission risk behaviors is an important secondary HIV prevention strategy. In addition to treatment for opioid dependence, addressing other substance use, social issues, particularly housing, and mental health may have important implications for reducing HIV transmission in HIV-infected opioid-dependent patients.

AB - Objective: This study was part of a national, multisite demonstration project evaluating the impact of integrated buprenorphine/naloxone treatment and HIV care. The goals of this study were to describe the baseline demographic, clinical, and substance use characteristics of the participants and to explore HIV transmission risk behaviors in this group. Methods: Nine sites across the United States participated. Data obtained by interview and chart review included demographic information, medical history, substance use, and risk behaviors. We performed a descriptive analysis of patient characteristics at entry and used logistic regression to evaluate factors associated with 1) unprotected anal or vaginal sex; and 2) needle-sharing within the previous 90 days. Results: Three hundred eighty-six individuals were included in the study: 303 (78.5%) received buprenorphine/naloxone; 41 (10.6%) received methadone; and 42 (10.9%) received another form of treatment. The analysis of risk behaviors was limited to those in the buprenorphine group (n = 303). Among those reporting vaginal or anal sex in the previous 90 days, 24% had sex without a condom. Factors significantly associated with unprotected sex were: having a partner; female gender; and alcohol use in previous 30 days. A total of 8.9% of participants shared needles in the previous 90 days. Factors significantly associated with needle-sharing were: amphetamine use; marijuana use; homelessness; and anxiety. Conclusions: Addressing transmission risk behaviors is an important secondary HIV prevention strategy. In addition to treatment for opioid dependence, addressing other substance use, social issues, particularly housing, and mental health may have important implications for reducing HIV transmission in HIV-infected opioid-dependent patients.

KW - buprenorphine

KW - heroin dependence

KW - HIV

KW - methadone

KW - opioid-related disorders

UR - http://www.scopus.com/inward/record.url?scp=79951792799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951792799&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e318209d3b9

DO - 10.1097/QAI.0b013e318209d3b9

M3 - Article

C2 - 21317589

AN - SCOPUS:79951792799

VL - 56

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - SUPPL. 1

ER -